ASSET PURCHASE
AGREEMENT
THIS ASSET
PURCHASE AGREEMENT (this "Agreement") is made and entered into as
of this 4th day of August, 2005, by and between IMCOR
Pharmaceutical Co., a Nevada corporation located at P.O. Box 2389,
La Jolla, CA 92037 (hereinafter known as “Seller”) and
NanoScan Imaging, LLC, a Pennsylvania limited liability company
located at 2250 Berks Road, Lansdale, PA 19446 (hereinafter known
as “Buyer”, and Buyer and Seller are hereinafter each
known as a “Party” and together known as the
“Parties”).
WITNESSETH:
WHEREAS, Seller
has been developing N1177, an iodine-based nanoparticulate contrast
agent, and PH-50, the same or a substantially similar compound for
a different indication;
WHEREAS, Seller
desires to sell to Buyer, and Buyer desires to buy from Seller, all
of its assets exclusively related to N1177 and PH-50 and the
development thereof (the “Business”), including without
limitation intellectual property rights and all related
documentation, manuals, notes, agreements and other assets
necessary or ancillary to the research and development of N1177 and
PH-50 (collectively, the “Assets”), all upon the terms
and conditions and subject to the limited exceptions set forth
herein;
NOW, THEREFORE,
in consideration of the mutual representations, warranties,
covenants, and agreements of the parties hereinafter set forth, the
parties hereto, intending to be legally bound, do hereby agree as
follows:
ARTICLE
I
PURCHASE AND SALE OF
ASSETS
1.1
Purchase and Sale of
Assets . Upon the terms
and subject to the conditions of this Agreement, Buyer agrees to
purchase, accept, and acquire from Seller, and Seller agrees to
sell, transfer, assign, convey, and deliver to Buyer, at the
Closing (as hereinafter defined) in accordance with the terms of
the Bill of Sale attached hereto as Exhibit A , and the
Assignment and Assumption Agreement attached hereto as Exhibit
B , all right, title and interest of Seller in and to the
Assets. Without in any way limiting the generality of the
foregoing, the Assets shall include all right, title and interest
owned or held by Seller in the following:
a.
N1177, a sterile, 150 mg/ml
NanoCrystal ® Colloidal Dispersion tested as a
parenteral iodinated x-ray contrast agent intended for use as a CT
lung imaging agent (but with other potential diagnostic
applications) which is being developed under Investigational New
Drug application 50,714 (the “IND”), and PH-50, which
has the same or substantially the same formulation and chemical
composition as N1177, but is delivered intravenously and used as a
blood pool agent for enhancing CT imaging of the circulatory
system, and all attendant rights, agreements and technical and
other documentation and correspondence, including but not limited
to the following:
|
|
i.
|
The IND,
including without limitation:
|
|
|
1.
|
All IND Annual
Reports, company executive summaries, and electronic files [IMCOR
and non-IMCOR]
|
|
|
ii
|
All
pharmacology and toxicology reports
|
|
|
iii.
|
All
pre-clinical study reports
|
|
|
1.
|
All study
reports for studies conducted by Photogen/IMCOR (i.e. MPI Research,
Provident Preclinical, imaging studies, toxicology reports,
pathology reports, etc.)
|
|
|
iv.
|
Any and all
rights (owned or licensed) to patents, copyrights, trademarks,
tradenames, and service marks, and applications or registrations
thereof, trade secrets, know how, processes, technical information
and documentation (“Technical Documentation”),
formulas, or other intellectual property relating or pertaining to
the Assets (collectively, the “Intellectual Property
Rights”).
|
|
|
|
|
|
|
v.
|
All rights
under the License Agreement by and between The General Hospital
Corporation (Massachusetts General Hospital) and Photogen, Inc.,
dated as of September 30, 1999 (the “License”), to the
extent possible, the Cooperative Research and Development Agreement
(“CRADA”) with the National Cancer Institute
(“NCT”), and any other license, consulting agreement,
or other contract relating to the Assets, including without
limitation those set forth on Schedule 1 attached hereto (together
with the License and CRADA, the “Assigned Contracts”),
and any correspondence and other documents relating
thereto.
|
|
|
|
|
|
|
vi.
|
All cGLP and
cGMP (N1177) Drug Product and N1177 and PH-50 Active Pharmaceutical
Ingredient supplies.
|
b.
Business Records
. All business, legal, regulatory
and marketing records and documents associated with the Assets,
including to the extent they exist operating records, contractor
and supplier documentation and correspondence, all clinical and
regulatory documents, including minutes of meetings and focus
groups, strategy documents and market analysis, asset ledgers,
inventory records, supplier lists, information and data respecting
leased or owned equipment, correspondence and mailing lists,
advertising materials and brochures, and other business records
used in the Business (the "Business Records"). Shipment of the
Business Records to the Buyer shall be at the expense of the
Buyer.
c.
Authorizations
. All known approvals,
authorizations, certifications, consents, variances, permissions,
licenses, and permits to or from, or filings, notices, or
recordings to or with, federal, state, and local governmental
authorities or other third parties related to the Business (the
Authorizations").
1.2
Exclusions
. The Assets shall not include any
other assets of Seller, including without limitation any cash,
investment accounts, accounts receivable, prepaid expenses, refunds
owed for any early cancellations of insurance policies or benefit
plans or any similar cash equivalent assets, stock and minute books
and other corporate records, payroll records and tax
returns.
ARTICLE
II
NO ASSUMPTION OF
LIABILITIES
Other than the
assumption of any obligations and liabilities accruing after the
Closing Date under the License and the other Assigned Contracts, at
and after the Closing, Buyer shall assume no liabilities of the
Seller.
ARTICLE
III
PRICE AND
PAYMENT
3.1
Purchase Price
. The aggregate purchase price for
the Assets (the “Purchase Price”) shall be One Hundred
Seven Thousand Five Hundred Dollars ($107,500).
3.2
Payment . On the Closing Date, Buyer shall pay Seventy
One Thousand Five Hundred Dollars ($71,500) of the Purchase Price
to Seller by wire transfer to Seller’s bank account pursuant
to wire instructions provided by Seller, and Three Thousand Five
Hundred Dollars ($3,500) of the Purchase Price by check to H.
Donlon Skerrett as a finder’s fee. Buyer will pay the
remaining balance of Thirty Two Thousand Five Hundred Dollars
($32,500) of the Purchase Price as follows: (i) Thirty One Thousand
Dollars ($31,000) to Seller by wire transfer upon receipt of the
Business Records and written verification that the payment
referenced in Section 3.3 has been made and accepted by MPI as full
and complete recognition and satisfaction of any amounts owing to
MPI, and (ii) One Thousand Five Hundred Dollars ($1,500) by check
to H. Donlon Skerrett as a finder’s fee upon payment of the
amount referenced in (i) above..
3.3
Within 10 days of Closing, Seller
will pay Ten Thousand Dollars ($10,000) to MPI as directed by MPI,
as full and complete recognition and satisfaction of all of
Seller’s prior obligations to MPI.
ARTICLE
IV
REPRESENTATIONS AND
WARRANTIES OF SELLER
Seller hereby
represents and warrants to Buyer as follows:
4.1
Organization and Standing of
Seller . Seller is a
corporation duly organized, validly existing and in good standing
under the laws of the State of Nevada and is qualified to do
business as a foreign corporation and is in good standing in the
State of California and such other states where the failure to be
so qualified and in good standing would affect the ability of
Seller to enter into this Agreement, consummate the transactions
contemplated thereby, or to operate the business of Seller as it
has previously been operated.
4.2
Power and Authority; Validity and
Enforceability . Seller
has the power and authority to operate its business as it has been
and is presently conducted and to execute, deliver, and perform
this Agreement and the other agreements and instruments to be
executed and delivered by it in connection with the transactions
contemplated hereby and thereby, it has taken all necessary action
to authorize the execution and delivery of this Agreement and such
other agreements and instruments and the consummation of the
transactions contemplated hereby and thereby. This Agreement is,
and the other agreements and instruments to be executed and
delivered by Seller in connection with the transactions
contemplated hereby shall be, the legal, valid and binding
obligations of Seller, enforceable in accordance with their
terms.
4.3
No Conflict
. Neither the execution and delivery
of this Agreement and the other agreements and instruments to be
executed and delivered in connection with the transactions
contemplated hereby or thereby, nor the consummation of the
transactions contemplated hereby or thereby, will violate or
conflict with (1) the Articles of Incorporation or Bylaws of
Seller, (2) to the Seller’s knowledge, any federal, state, or
local law, regulation, ordinance, governmental restriction, order,
judgment, or decree applicable to Seller or the Assets or Business,
or (3) any mortgage, indenture, license, instrument, trust,
contract, agreement, or other commitment or arrangement to which
Seller is a party or by which Seller or any of the Assets is
bound.
4.4
Litigation
. Except as set forth on Schedule
4.4, there are no pending or threatened actions, suits, written or
oral claims, litigation at law or in equity, or any proceedings of
any kind, whether before a court, an arbitration or before any
commission or administrative or governmental authority or agency
against or involving Seller or any of its assets, including the
Assets.
4.5
Required Contract
Consents . No approval,
authorization, consent, permission, or waiver to or from, or
notice, filing, or recording to or with, any person is necessary
for (1) the execution and delivery of this Agreement and the other
agreements and instruments to be executed and delivered in
connection with the transactions contemplated hereby or thereby by
Seller or the consummation by Seller of the transactions
contemplated hereby; (2) the transfer and assignment to Buyer at
Closing of the Assigned Contracts and other Assets, or (3) the
ownership and use of the Assets.
4.6
Asset Encumbrances
. There are no liabilities or
obligations of Seller with respect to the Business or the Assets of
any kind whatsoever, whether or not accrued, contingent or
absolute, determined or determinable, and there is no existing
condition, situation or set of circumstances, including without
limitation any verbal or written agreements or arrangements between
Seller and/or one of its creditors, shareholder or any third
parties, which could result in such liability or
obligation.
4.7
Taxes . There are no liens for taxes other than for
current taxes not yet due and payable upon the Assets.
4.8
Title to Tangible
Property . Buyer at
Closing shall obtain good and marketable title to all of the
tangible Assets (i.e., raw material, Technical Documentation,
Equipment, and Business Records), free and clear of all title
defects, liens, restrictions, claims, charges, security interests,
or other encumbrances of any nature whatsoever, including any
mortgages leases, chattel mortgages, conditional sales contracts,
collateral security arrangements, or other title or interest
retention arrangements. To the Seller’s knowledge, all of the
tangible Assets are in good operating order, condition, and repair,
ordinary wear and tear excepted, and are suitable for use in the
ordinary course. Between March 31, 2005 and the Closing Date, to
the Seller’s knowledge, there has not been any material
adverse degradation to the general condition or value of the
Assets, other than in the ordinary course.
4.9
Title to Intellectual Property
Rights .
a.
Ownership . Seller is the owner of the Intellectual
Property Rights that Buyer shall receive at Closing. Schedule 1.1
sets forth all trademarks and service marks, all trade names, all
copyrights, and all filed patent applications and issued patents
owned or licensed by Seller and used for the operation of the
Business relating to the Assets as heretofore operated.
b.
Absence of Claims
. No claims have been asserted by
any person or entity for the use of the Intellectual Property
Rights, and Seller does not know of any valid basis for any such
claim. The use of the Intellectual Property Rights by the Seller
does not infringe on or misappropriate the patent, trademark,
copyright, trade secret or other intellectual property or ownership
rights of any third party.
4.10
Adequacy of Technical
Documentation . The
Technical Documentation includes all documentation used in the
Business as well as any pertinent commentary or explanation that
may be necessary to render such materials understandable and usable
by trained personnel in the life sciences diagnostic
industry.
4.11
Assigned Contracts
. The Assigned Contracts listed in
Schedule 1.1 constitute the material contracts, agreements,
licenses, and other commitments and arrangements necessary or
advisable for the conduct of the Business and use of the Assets as
previously conducted and used, and an accurate and complete copy of
each of the Assigned Contracts has been supplied to Buyer. Each
Assigned Contract, including the License: (i) sets forth the entire
agreement and understanding between Seller and the other parties
thereto; and (ii) is valid, binding and in full force and effect,
and there is no event which has occurred or exists, which
constitutes or which, with notice, the happening of any event
(including the sale of the Assets) and/or the passage of time would
constitute a default or breach under any such Assigned Contract by
Seller, or, to Seller’s knowledge, any other party thereto,
or would cause the acceleration of any obligation of any party
thereto or give rise to any right of termination or